GLP-1 Drugs: What 977 SEC Filings Reveal

GLP-1 drugs appear in 977 operational SEC filings across 15+ industries — and the most important finding isn't the pharmaceutical companies making them. It's the ecosystem forming around them. Eli Lilly's Mounjaro and Zepbound now account for 56% of the company's total revenue, creating the highest single-drug-class dependency in large-cap pharma. But that concentration is simultaneously catalyzing an unbundling of the GLP-1 value chain across industries that have nothing to do with drug development: compound pharmacies distributing cheaper alternatives, a 60-year-old weight management brand that now prescribes injectable drugs, and a medical device startup with FDA designation specifically for patients who stop taking GLP-1s. Reading any one of these filings shows a company managing GLP-1 exposure. Reading all 977 reveals a platform economy forming in real time.

Eli Lilly: 56% of Revenue From One Drug Class

Eli Lilly's 10-K reveals a revenue concentration that would trigger alarm in any other context. Mounjaro and Zepbound — both built on tirzepatide — collectively generated more than 56% of total revenue in 2025, with each product individually exceeding $3 billion. Including Trulicity, an older GLP-1, and three other blockbusters, 82% of LLY's revenue depends on just six products.

"We derived direct product and/or collaboration and other revenues of more than $3 billion for each of Mounjaro, Zepbound, Verzenio, Trulicity, Taltz, and Jardiance (including Glyxambi, Synjardy, and Trijardy XR) that collectively accounted for 82 percent of our total revenues in 2025. In particular, Mounjaro and Zepbound accounted for 56 percent of our total revenues in 2025, and we expect cardiometabolic health products will continue to represent a significant and growing portion of our business, revenues"

This concentration explains LLY's combative language toward compounders. The same filing describes "counterfeit, misbranded, adulterated, and mass-compounded incretins" as a material threat — language designed to frame any compound GLP-1 as illegitimate. When 56% of revenue depends on two products, the compound pharmacy market isn't a nuisance; it's an existential risk vector that LLY is fighting through FDA petitions, legal action, and public regulatory pressure.

Eli Lilly's 56% revenue concentration in two tirzepatide products represents the highest single-drug-class dependency among large-cap pharma companies, making its anti-compounding campaign a financial necessity rather than a strategic choice.

Hims & Hers: Named by the FDA

On the other side of LLY's campaign sits Hims & Hers Health. HIMS launched compound injectable semaglutide in May 2024 through its telehealth platform — a company classified under SIC 8011 (health services), not pharmaceuticals, building a major revenue line on compound GLP-1 distribution. The regulatory collision arrived fast.

"In February 2026, the FDA issued a statement (the "FDA Statement") indicating that the agency intends to restrict GLP-1 active pharmaceutical ingredients intended for use in non-FDA-approved compounded drugs that are being mass-marketed as similar alternatives to FDA-approved drugs. We were directly named in the FDA Statement."

The pressure is multilayered. The FDA resolved the semaglutide shortage on February 21, 2025, cutting off HIMS's access to 503B outsourcing facilities. Branded manufacturers — including Lilly and Novo Nordisk — have petitioned to add semaglutide and tirzepatide to the "Demonstrable Difficulties for Compounding List." HIMS now operates exclusively through 503A compounding pharmacies, which constrain its ability to fulfill at scale. The LLY and HIMS filings are two sides of the same coin: one company's 56% revenue concentration creates the economic incentive for the other's compound distribution business, and both disclose the resulting collision.

Hims & Hers Health was directly named in an FDA enforcement statement in February 2026, making it the most visible regulatory target in the compound GLP-1 market that branded manufacturers are spending aggressively to shut down.

Weight Watchers: The 60-Year Pivot

Weight Watchers' 10-K contains perhaps the most structurally surprising disclosure in the GLP-1 filing universe. A company classified under SIC 7200 (personal services) now prescribes injectable GLP-1 medications through board-certified obesity medicine clinicians via its Med+ clinical tier. Its Med+ formulary includes "both the oral and injectable versions of GLP-1s" with care coordinators who facilitate insurance coverage. The company also built a dedicated GLP-1 Success Program within its Core+ subscription tier, providing medication-specific nutrition guidance, dose tracking, side effect management strategies, and strength-building plans to help preserve muscle mass — addressing one of GLP-1 therapy's best-known side effects.

"GLP-1 Success Program: Tailors all aspects of our behavioral support program to help members using GLP-1 medications drive more effective and sustainable results. The program, which is available to members whether they receive their GLP-1 prescription through Weight Watchers or from other providers, provides personalized nutrition guidance to help members meet important macronutrient goals, tools to track weight loss and medication doses, strategies and support for managing side effects, and strength-building plans to help preserve muscle mass."

WW isn't just surviving GLP-1 disruption — it's positioning as an infrastructure layer for GLP-1 drug utilization. The company captures revenue whether members get their GLP-1 prescription through Weight Watchers or from another provider, making it agnostic to the compounding versus branded drug battle playing out between HIMS and LLY.

Weight Watchers' transformation from a behavioral weight management company to a GLP-1 clinical platform demonstrates how a single drug class can force complete business identity restatement across an entire adjacent industry.

Fractyl Health: The FDA-Designated Off-Ramp

While WW helps patients stay on GLP-1s, Fractyl Health (GUTS) is building the opposite solution. Fractyl's Revita system has FDA Breakthrough Device designation specifically for weight maintenance after GLP-1 discontinuation — the first device designation that presupposes the existence of another therapy class.

"Revita has U.S. FDA Breakthrough Device designation in weight maintenance for people with obesity who discontinue GLP-1 based therapy."

The REVEAL-1 clinical study (n=22) enrolls patients who have lost at least 15% of body weight on a GLP-1 and who "need or choose to discontinue GLP-1 based therapy." Revita uses hydrothermal ablation to resurface the duodenal lining — a one-time procedure targeting the gut signaling mechanisms that cause weight regain after stopping GLP-1s. Fractyl is a medical instruments company (SIC 3841) whose entire regulatory and clinical strategy depends on GLP-1 drugs existing, succeeding, and then creating a discontinuation problem large enough to sustain a device market.

Fractyl Health's FDA Breakthrough Device designation for GLP-1 discontinuation represents the first regulatory acknowledgment that GLP-1 weight regain is a distinct medical need, creating a device market category that wouldn't exist without the drugs it follows.

Amgen: The $7.3 Billion Late Entry

Amgen's entry via MariTide shows the competitive landscape remains unsettled. MariTide is an antibody-peptide conjugate that activates the GLP-1 receptor while antagonizing the GIPR — a mechanistically different approach from Lilly's dual agonist tirzepatide — with two Phase 3 studies initiated in March 2025.

"In March 2025, we announced the initiation of two global Phase 3 studies to evaluate MariTide, a differentiated antibody-peptide conjugate that activates the glucagon like peptide 1 (GLP-1) receptor and antagonizes the glucose-dependent insulinotropic polypeptide receptor (GIPR), in chronic weight management: one study in adults living with obesity or overweight without Type 2 diabetes and another study in adults living with obesity or overweight with Type 2 diabetes."

The capital commitment tells the story. Amgen's R&D spending surged 22% to $7.3 billion in 2025, with Later-Stage Clinical Programs rising 53% from $2.8 billion to $4.3 billion — driven partly by MariTide. A second obesity candidate, AMG 513, sits in Phase 1. The antibody-peptide conjugate format could enable less-frequent dosing, potentially disrupting the weekly injection economics that currently define the market.

Amgen's $1.5 billion increase in Later-Stage Clinical Programs spending reflects how GLP-1 competition is driving one of the largest single-year R&D allocation shifts in large-cap biotech.

The Pattern: GLP-1 as Platform Economy

What 977 SEC filings reveal is that GLP-1 drugs are functioning as a platform, not just a drug class. The drugs generate the primary revenue stream — LLY's 56% concentration makes that clear — but adoption, regulation, side effects, and discontinuation are spawning an ecosystem of dependent business models across unrelated industries.

The evidence maps to a clear lifecycle. LLY and Amgen compete on the drug itself. HIMS distributes compound alternatives through a regulatory gray zone that LLY is actively trying to close. WW has repositioned as adherence infrastructure, capturing revenue from GLP-1 utilization regardless of which company supplies the drug. Fractyl addresses the endpoint: what happens when patients stop. Each company's filing makes sense individually. Together, they map an economic structure where non-pharma companies build revenue models around every phase of the GLP-1 patient journey.

Three observable developments to watch:

1. The compounding resolution. If branded manufacturers succeed in adding semaglutide to the Demonstrable Difficulties list, HIMS's compound GLP-1 business faces an existential regulatory event — and LLY's defensive spending decreases.
2. WW's GLP-1 subscriber mix. The proportion of Core+ and Med+ subscribers using GLP-1-specific programs will determine whether WW has built a sustainable clinical business or a temporary positioning pivot.
3. Fractyl's REVEAL-1 readout. If Revita demonstrates durable weight maintenance post-GLP-1 discontinuation, it validates a device market category that depends on — but doesn't compete with — GLP-1 drugs.

Frequently Asked Questions

What are GLP-1 drugs and why do they appear in so many SEC filings?

GLP-1 receptor agonists are medications originally developed for type 2 diabetes that have shown dramatic effectiveness for weight management. They appear in 977 operational SEC filings across 15+ industries because their market impact extends beyond pharmaceuticals — affecting medical devices, telehealth, weight management, drug distribution, and even food and beverage companies discussing changing consumer behavior.

Which company has the highest financial exposure to GLP-1 drugs?

Eli Lilly has the highest concentration, with Mounjaro and Zepbound accounting for 56% of total revenue in 2025. Each product individually exceeded $3 billion. This makes LLY's financial performance more dependent on a single drug class than any other large-cap pharmaceutical company.

What is the FDA doing about compound GLP-1 drugs?

The FDA issued a February 2026 enforcement statement targeting mass-marketed compound GLP-1s, directly naming Hims & Hers Health. The agency resolved the semaglutide shortage in February 2025, restricting 503B outsourcing facility compounding. Branded manufacturers have petitioned to add semaglutide and tirzepatide to the Demonstrable Difficulties for Compounding List, which would further restrict compound alternatives.

How is Weight Watchers responding to GLP-1 disruption?

WW pivoted its entire business model rather than treating GLP-1 drugs as a threat. The company now prescribes FDA-approved GLP-1 medications through its Med+ clinical tier with board-certified obesity medicine clinicians, and offers a dedicated GLP-1 Success Program with medication-specific nutrition guidance, dose tracking, and muscle mass preservation plans through its Core+ subscription.

Are there medical devices being developed specifically for GLP-1 patients?

Yes. Fractyl Health's Revita device has FDA Breakthrough Device designation specifically for weight maintenance in patients who discontinue GLP-1 therapy. The REVEAL-1 clinical study (n=22) targets patients who have lost at least 15% of body weight on GLP-1s and need or choose to stop. The device uses hydrothermal ablation to resurface the duodenal lining, addressing gut signaling mechanisms responsible for post-GLP-1 weight regain.

What new GLP-1 competitors are entering the market?

Amgen initiated two Phase 3 studies for MariTide in March 2025. MariTide uses a differentiated antibody-peptide conjugate that activates GLP-1 receptors while antagonizing GIPR — a different mechanism from Lilly's dual agonist tirzepatide. Amgen's R&D spending increased 22% to $7.3 billion in 2025, with Later-Stage Clinical Programs up 53% to $4.3 billion, driven partly by the MariTide program.

Methodology

This analysis used MetricDuck's SEC filing intelligence tools to search 1,717 filings across 27 form types for mentions of GLP-1 drugs, semaglutide, and tirzepatide. We filtered to 977 operational filings (10-K, 10-Q, 8-K, S-1, DEF 14A) and identified 5 companies with substantive disclosures spanning 4 distinct SIC industries for deep analysis.

Tools used: SEC EDGAR Full-Text Search (EFTS) for filing discovery across the complete EDGAR corpus, MetricDuck filing intelligence for company-level signal extraction, and filing section reader for verbatim evidence retrieval from specific 10-K sections.

Limitations:

• Keyword matching scope: The EFTS query ("GLP-1" OR "semaglutide" OR "tirzepatide") captures explicit mentions but misses filings that discuss weight loss drug impact without naming specific molecules. Companies in food, beverage, or fitness industries may describe GLP-1 market effects using generic terms like "weight loss medications" that this search would not capture.
• Filing date range: Results cover March 2025 to March 2026. Earlier filings from the initial GLP-1 market expansion (2023-2024) are not included, potentially missing companies that discussed GLP-1 exposure in prior periods.
• Qualitative extraction: Filing quotes are extracted from specific 10-K sections (Risk Factors, Business Description, MD&A). Companies may discuss GLP-1 impact in earnings call transcripts, investor presentations, or proxy statements not captured by this section-level analysis.

Disclaimer: This analysis is for informational purposes only and does not constitute investment advice. The author does not hold positions in LLY, HIMS, WW, GUTS, or AMGN. Past performance and current metrics do not guarantee future results. All data is derived from public SEC filings and may contain errors or omissions from the automated extraction process.